BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Esposito G, Pucciarelli S, Alaggio R, Giacomelli L, Marchiori E, Iaderosa GA, Friso ML, Toppan P, Chieco-Bianchi L, Lise M. P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol. 2001;8:311-318. [PMID: 11352304 DOI: 10.1007/s10434-001-0311-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Moreno-galindo C, Hermsen M, García-pedrero JM, Fresno MF, Suárez C, Rodrigo JP. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncology 2014;50:128-34. [DOI: 10.1016/j.oraloncology.2013.10.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
2 Karagkounis G, Kalady MF. Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information? Clin Colon Rectal Surg 2017;30:415-22. [PMID: 29184477 DOI: 10.1055/s-0037-1606373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Lebe B, Sarioğlu S, Sökmen S, Ellidokuz H, Füzün M, Küpelioğlu A. The clinical significance of p53, p21, and p27 expressions in rectal carcinoma. Appl Immunohistochem Mol Morphol 2005;13:38-44. [PMID: 15722792 DOI: 10.1097/00129039-200503000-00007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Gao X, Saha D, Kapur P, Anthony T, Livingston EH, Huerta S. Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate. J Surg Oncol. 2009;100:149-158. [PMID: 19507186 DOI: 10.1002/jso.21318] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
5 Minsky B. Role of adjuvant therapy in rectal cancer: EDITORIAL. ANZ Journal of Surgery 2002;72:773-4. [DOI: 10.1046/j.1445-2197.2002.02575.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Akiyoshi T, Kobunai T, Watanabe T. Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today. 2012;42:713-719. [PMID: 22706722 DOI: 10.1007/s00595-012-0223-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
7 Moore HG, Shia J, Klimstra DS, Ruo L, Mazumdar M, Schwartz GK, Minsky BD, Saltz L, Guillem JG. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol 2004;11:955-61. [PMID: 15525823 DOI: 10.1245/ASO.2004.03.095] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
8 Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47:1798-1807. [PMID: 15622571 DOI: 10.1007/s10350-004-0681-1] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 7.1] [Reference Citation Analysis]
9 Restivo A, Zorcolo L, Cocco IM, Manunza R, Margiani C, Marongiu L, Casula G. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol. 2013;20:864-871. [PMID: 23010737 DOI: 10.1245/s10434-012-2669-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
10 Inomata M, Akagi T, Nakajima K, Etoh T, Tahara K, Matsumoto T, Ogawa T, Fujii K, Shiromizu A, Kitano S. A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial. Mol Clin Oncol 2016;4:510-4. [PMID: 27073652 DOI: 10.3892/mco.2016.767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
11 Minsky BD. Combined-Modality Therapy of Rectal Cancer with Oxaliplatin-Based Regimens. Clinical Colorectal Cancer 2004;4:S29-36. [DOI: 10.3816/ccc.2004.s.005] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
12 Minsky BD. Radiation plus chemotherapy as adjuvant therapy for rectal cancer. Best Practice & Research Clinical Gastroenterology 2002;16:267-82. [DOI: 10.1053/bega.2002.0285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Lin LC, Lee HH, Hwang WS, Li CF, Huang CT, Que J, Lin KL, Lin FC, Lu CL. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol. 2006;15:211-216. [PMID: 17360176 DOI: 10.1016/j.suronc.2007.01.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
14 Grimminger PP, Shi M, Barrett C, Lebwohl D, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, Winder T, Lenz HJ. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. Pharmacogenomics J. 2012;12:404-411. [PMID: 21788964 DOI: 10.1038/tpj.2011.29] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
15 Minsky BD. Adjuvant therapy of resectable rectal cancer. Cancer Treat Rev. 2002;28:181-188. [PMID: 12363458 DOI: 10.1016/S0305-7372(02)00037-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
16 Huang MY, Huang CW, Wang JY. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Kaohsiung J Med Sci 2020;36:152-9. [PMID: 31814296 DOI: 10.1002/kjm2.12161] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Leibold T, Hui VW, Shia J, Ruby JA, Riedel ER, Guillem JG. p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease. Am J Surg 2014;208:228-34. [PMID: 24814310 DOI: 10.1016/j.amjsurg.2014.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006;93:145-150. [PMID: 16425302 DOI: 10.1002/jso.20320] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 4.4] [Reference Citation Analysis]
19 Grimminger PP, Brabender J, Warnecke-Eberz U, Narumiya K, Wandhöfer C, Drebber U, Bollschweiler E, Hölscher AH, Metzger R, Vallböhmer D. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res 2010;164:e61-6. [PMID: 20863523 DOI: 10.1016/j.jss.2010.08.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
20 Ramzan Z, Nassri AB, Huerta S. Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer. World J Gastrointest Oncol 2014; 6(7): 194-210 [PMID: 25024812 DOI: 10.4251/wjgo.v6.i7.194] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
21 Ozden SA, Ozyurt H, Ozgen Z, Kilinc O, Oncel M, Gul AE, Karadayi N, Serakinci N, Kan B, Orun O. Prognostic role of sensitive-to-apoptosis gene expression in rectal cancer. World J Gastroenterol 2011; 17(44): 4905-4910 [PMID: 22171132 DOI: 10.3748/wjg.v17.i44.4905] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
22 Rengan R, Paty PB, Wong WD, Guillem JG, Weiser M, Temple L, Saltz L, Minsky BD. Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders. Clin Colorectal Cancer. 2006;5:413-421. [PMID: 16635280 DOI: 10.3816/CCC.2006.n.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
23 Valentini V. Radiotherapy in rectal cancer: technical aspects and regimens. European Journal of Cancer Supplements 2005;3:373-88. [DOI: 10.1016/s1359-6349(05)80298-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch T, Ried T. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826-38. [PMID: 15774776 DOI: 10.1200/JCO.2005.00.406] [Cited by in Crossref: 259] [Cited by in F6Publishing: 89] [Article Influence: 16.2] [Reference Citation Analysis]
25 Milgrom SA, Garcia-aguilar J. Molecular biomarkers as predictors of response to neoadjuvant chemoradiation therapy in rectal cancer. Seminars in Colon and Rectal Surgery 2013;24:119-24. [DOI: 10.1053/j.scrs.2013.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Baldus SE, M�nig SP, Schr�der W, Metzger R, Lang S, Zirbes TK, Thiele J, M�ller RP, Dienes HP, H�lscher AH, Schneider PM. Regression von �sophaguskarzinomen nach neoadjuvanter Radiochemotherapie: Kriterien der histopathologischen Evaluation. Pathologe 2004;25:421-7. [DOI: 10.1007/s00292-004-0697-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
27 Cuadrado M, Gutierrez-Martinez P, Swat A, Nebreda AR, Fernandez-Capetillo O. p27Kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage. Cancer Res 2009;69:8726-32. [PMID: 19843869 DOI: 10.1158/0008-5472.CAN-09-0729] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
28 Ojima E, Inoue Y, Miki C, Mori M, Kusunoki M. Effectiveness of gene expression profiling for response prediction of rectal cancer to preoperative radiotherapy. J Gastroenterol 2007;42:730-6. [DOI: 10.1007/s00535-007-2089-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kim NK, Hur H. New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer. Yonsei Med J. 2015;56:1461-1477. [PMID: 26446626 DOI: 10.3349/ymj.2015.56.6.1461] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
30 Xu B, Chen Y, Guo Y, Zhou D, Yue Z, Duan Q, Yang Y, Guan G, Chi P, Lin C. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma. Am J Clin Oncol 2018;41:601-6. [PMID: 27672742 DOI: 10.1097/COC.0000000000000333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Valentini V, Gambacorta MA, Barba MC. Could the surgeon trust to radiotherapy help in rectal cancer? Acta Chir Iugosl 2008;55:55-9. [PMID: 19069693 DOI: 10.2298/aci0803055v] [Reference Citation Analysis]
32 Ferrigno R, Novaes PE, Silva ML, Nishimoto IN, Nakagawa WT, Rossi BM, Ferreira Fde O, Lopes A. Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors. Radiat Oncol 2006;1:5. [PMID: 16722598 DOI: 10.1186/1748-717X-1-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
33 Yılmaz Rakıcı S, Bedir R, Hatipoğlu C. Are there predictors that can determine neoadjuvant treatment responses in rectal cancer? Turk J Gastroenterol 2019;30:220-7. [PMID: 30459135 DOI: 10.5152/tjg.2018.18179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Huerta S, Gao X, Saha D. Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn. 2009;9:469-480. [PMID: 19580431 DOI: 10.1586/erm.09.26] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
35 Minsky BD. Combined modality therapy for rectal cancer. Elsevier; 2003. pp. 803-16. [DOI: 10.1016/s0921-4410(03)21038-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Grade M, Gaedcke J, Wangsa D, Varma S, Beckmann J, Liersch T, Hess C, Becker H, Difilippantonio MJ, Ried T, Ghadimi BM. Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. Cancer Genet Cytogenet 2009;193:19-28. [PMID: 19602460 DOI: 10.1016/j.cancergencyto.2009.03.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
37 Qiu HZ, Wu B, Xiao Y, Lin GL. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. Colorectal Dis. 2011;13:1353-1360. [PMID: 21689282 DOI: 10.1111/j.1463-1318.2011.02570.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
38 Huerta S, Hrom J, Gao X, Saha D, Anthony T, Reinhart H, Kapur P. Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Dig Liver Dis. 2010;42:679-684. [PMID: 20227932 DOI: 10.1016/j.dld.2010.02.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
39 Hur H, Kim NK, Min BS, Baik SH, Lee KY, Koom WS, Ahn JB, Kim H. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer? Dis Colon Rectum. 2014;57:592-601. [PMID: 24819099 DOI: 10.1097/DCR.0000000000000109] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
40 Agostini M, Zangrando A, Pastrello C, D'Angelo E, Romano G, Giovannoni R, Giordan M, Maretto I, Bedin C, Zanon C, Digito M, Esposito G, Mescoli C, Lavitrano M, Rizzolio F, Jurisica I, Giordano A, Pucciarelli S, Nitti D. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol Ther 2015;16:1160-71. [PMID: 26023803 DOI: 10.1080/15384047.2015.1046652] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
41 Edden Y, Wexner SD, Berho M. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma: Molecular markers in rectal cancers. Colorectal Disease 2012;14:555-61. [DOI: 10.1111/j.1463-1318.2011.02697.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
42 Del Gobbo A, Ferrero S. Immunohistochemical Markers as Predictors of Histopathologic Response and Prognosis in Rectal Cancer Treated with Preoperative Adjuvant Therapy: State of the Art. Gastroenterol Res Pract 2017;2017:2808235. [PMID: 28326100 DOI: 10.1155/2017/2808235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Valentini V, Beets-Tan R, Borras JM, Krivokapić Z, Leer JW, Påhlman L, Rödel C, Schmoll HJ, Scott N, Velde CV, Verfaillie C. Evidence and research in rectal cancer. Radiother Oncol 2008;87:449-74. [PMID: 18534701 DOI: 10.1016/j.radonc.2008.05.022] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 6.4] [Reference Citation Analysis]
44 Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74:673-688. [PMID: 19480968 DOI: 10.1016/j.ijrobp.2009.03.003] [Cited by in Crossref: 170] [Cited by in F6Publishing: 160] [Article Influence: 14.2] [Reference Citation Analysis]
45 Günther K, Dimmler A, Rödel F, Reulbach U, Merkel S, Bittorf BR, Matzel KE, Papadopoulos T, Hohenberger W, Sauer R, Rödel C. P27 does not predict histopathological response to radiochemotherapy in rectal cancer. J Surg Res 2003;113:179-88. [PMID: 12957127 DOI: 10.1016/s0022-4804(03)00049-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
46 Kobayashi H, Hashiguchi Y, Ueno H, Shinto E, Kajiwara Y, Mochizuki H. Absence of Cyclooxygenase-2 Protein Expression is a Predictor of Tumor Regression in Rectal Cancer Treated with Preoperative Short-Term Chemoradiotherapy. Diseases of the Colon & Rectum 2007;50:1354-62. [DOI: 10.1007/s10350-006-0881-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]